HUTCHMED (China) Ltd (HCM) stock
HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
$14.40−0.33 (-2.24%)
Close on Nov 17, 2026Market cap $2.51BP/E 5.5Yield –
HUTCHMED (China) r&d expenses
Research and development expenses are spending on new products and technology.
HUTCHMED (China)'s R&D Expenses for the twelve months ending Dec 31, 2019 was $138.19M, up 21.0% year over year. For fiscal 2025 it was $148.30M, down 30.1% from the year before. Over ten years it grew 12.1% a year on average. The highest annual figure on record is $386.89M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $148.30M | -30.1% |
| FY2024 | Dec 31, 2024 | $212.11M | -29.8% |
| FY2023 | Dec 31, 2023 | $302.00M | -21.9% |
| FY2022 | Dec 31, 2022 | $386.89M | +29.4% |
| FY2021 | Dec 31, 2021 | $299.09M | +71.1% |
| FY2020 | Dec 31, 2020 | $174.78M | +26.5% |
| FY2019 | Dec 31, 2019 | $138.19M | +21.0% |
| FY2018 | Dec 31, 2018 | $114.16M | +51.2% |
| FY2017 | Dec 31, 2017 | $75.52M | +12.9% |
| FY2016 | Dec 31, 2016 | $66.87M | +41.2% |
| FY2015 | Dec 31, 2015 | $47.37M | +58.3% |
| FY2014 | Dec 31, 2014 | $29.91M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2019 | Dec 31, 2019 | $37.46M | +47.3% |
| Q3 FY2019 | Sep 30, 2019 | $31.45M | +9.7% |
| Q2 FY2019 | Jun 30, 2019 | $36.01M | +14.7% |
| Q1 FY2019 | Mar 31, 2019 | $33.28M | +16.1% |
| Q4 FY2018 | Dec 31, 2018 | $25.43M | – |
| Q3 FY2018 | Sep 30, 2018 | $28.68M | – |
| Q2 FY2018 | Jun 30, 2018 | $31.39M | – |
| Q1 FY2018 | Mar 31, 2018 | $28.66M | – |
See a number that looks wrong?